Is NICE’s Pricing Influence On The Wane?
The pricing of medicines may appear as a mystery to many; theories range from what the market will bear to prices being based on value. The Pink Sheet examines the role of two key players with influence in drug pricing in the UK – health technology assessment body NICE, which decides whether a product is value for money, and NHS England, which leads the tax-funded national health service in England and pays for new specialized drugs.
You may also be interested in...
The Swiss major has been enthusing about its population-based agreement in the UK for the investigational gene silencing cholesterol lower and plans for similar schemes in other countries.
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.